BOOM: Covid Vaccine Number 2

[SueEllen]

Moderna Covid vaccine candidate almost 95% effective, trials show | Coronavirus | The Guardian

The race for a coronavirus vaccine has received another shot in the arm with the US biotech firm Moderna becoming the latest to reveal impressive results from phase 3 trials of its jab.

An interim analysis released on Monday, and based on 95 patients with confirmed Covid infections, found the candidate vaccine has an efficacy of 94.5%. The company said it now plans to apply to the US regulator, the Food and Drug Administration, for emergency-use authorisation in the coming weeks. In the trial, 90 of the patients received the placebo with the remaining five the vaccine.

The results are the latest encouraging news to emerge from the breakneck effort to develop a vaccine against coronavirus and follow a similar interim analysis earlier this month from a collaboration between Pfizer and the German firm BioNTech, which suggest its vaccine is 90% effective at preventing illness.

The Moderna vaccine is not expected to be available outside the US until next year. The biotech said it would have 20 million doses ready to ship in the US before the end of 2020 and hoped to manufacture 500 million to one billion doses globally next year.

[SueEllen]

Good points - ....it can be stored at standard refrigeration temperatures of 2C to 8C for 30 days. It can be stored for six months at -20C for shipping and long-term storage, the company said.
Here are the major hurdles ahead for Covid-19 vaccine distribution in the U

Bad points - ...But at £38 to £45 for a course of two shots, Moderna’s vaccine is more expensive than the other frontrunners. AstraZeneca and Oxford University are aiming to sell their vaccine at about £3 a dose, while vaccines in trial with Johnson and Johnson and a collaboration between Sanofi and GSK are both expected to cost about £8 per dose. Pfizer is charging the US about £30 for a two-shot course. The UK has ordered 40m Pfizer shots but none of the Moderna vaccine

[Paddy]

I just wonder how much the US general public will have to pay to be vaccinated.

[SueEllen]

I just wonder how much the US general public will have to pay to be vaccinated.

This is why the Oxford vaccine (or any other one) that is cheap is needed. We need most of the world vaccinated not just the wealthy.

[vetran]

I just wonder how much the US general public will have to pay to be vaccinated.

A bit more than we did to get Boris laid.

[darmstadt]

this is what has been ordered:

100m doses of University of Oxford/AstraZeneca vaccine (in phase 3 clinical trials)40m doses of BioNTech/Pfizer vaccine (in phase 3 clinical trials)
60m doses of Novavax vaccine (in phase 3 clinical trials)
60m doses of Valneva vaccine (in pre-clinical trials)
60m doses of GSK/Sanofi Pasteur vaccine (in phase 1 clinical trials)
30m doses of Janssen vaccine (in phase 2 clinical trials)

[FIERCE TANK BATTLE]

An interim analysis released on Monday, and based on 95 patients with confirmed Covid infections, found the candidate vaccine has an efficacy of 94.5%. The company said it now plans to apply to the US regulator, the Food and Drug Administration, for emergency-use authorisation in the coming weeks. In the trial, 90 of the patients received the placebo with the remaining five the vaccine.

I'm no maths genius, but 94.5% effacacy would mean 4.725 people didn't get the 'rona after taking it, wouldn't it?

How'd they figure that out?

[NickFitz]

Apparently Matt Hancock said several months ago that there was no need to order any of this one because the government would do a much better job of creating a vaccine anyway, or something equally dumb

[SueEllen]

Apparently Matt Hancock said several months ago that there was no need to order any of this one because the government would do a much better job of creating a vaccine anyway, or something equally dumb

No Tory MP was and is linked to Moderna more likely.

[jayn200]

I'm no maths genius, but 94.5% effacacy would mean 4.725 people didn't get the 'rona after taking it, wouldn't it?

How'd they figure that out?

To get the exact figure you'd have to know how many participants in each group, it might not be the same. I haven't seen how many, not sure if that information is out there.